Ivantist Treats Glaucoma
Ivantis Microstent Technology
Ivantis MicroStent News & Events

The Hydrus Microstent Ivantis HYDRUS IV United States Clinical Trial

Contact Ivantis Microstent Developers

Ivantis, Inc. is a company dedicated to the development of new and innovative solutions for glaucoma. Current therapies for primary open angle glaucoma (POAG) include eye drops, laser therapy, and surgery. But each of these has its limitations. Glaucoma remains the leading cause of blindness worldwide, in need of better treatment alternatives. It is our goal to develop new and effective solutions for ophthalmology specialists and the 70 million people worldwide who are affected by this debilitating and sight-stealing disease.

What's New

Ivantis Raises $25 Million Series C to Fund Future US Commercialization of the Hydrus™ Microstent for Minimally Invasive Glaucoma Surgery (MIGS)

Ivantis Completes Enrollment in Pivotal HYDRUS IV Glaucoma Study of the Hydrus™ Microstent (April, 2015)

Ivantis blue ribbon award

Ivantis Wins "Best of Session" Award at ASCRS

Ivantis recently won a Blue Ribbon award for our presentation on the use of Hydrus Technology. See it by clicking here.